Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- US FDA Issues Warning Letter Over GMP Violations by Daiichi Sankyo Subsidiary
September 15, 2011
- MHLW to Survey “Family Pharmacy” Function Toward Next Revision of Dispensing Fees
September 15, 2011
- US Proposes Elimination of Tariff on Drugs: TPP Talks
September 14, 2011
- MHLW to Continue to Promote Non-proprietary Name-based Brand Names for GE Drugs
September 14, 2011
- ”GMP Team” to Begin Mock GMP Inspections in Kinki Region from Next February
September 14, 2011
- MHLW Permits Ongoing Internet Sales of Reclassified Class 2 Drugs as Provisional Measure
September 13, 2011
- MHLW Minister Komiyama to Push Drug Industry Development Through Government-Private Sector Cooperation
September 13, 2011
- PAFSC: “No Direct Correlation” Between HPV Vaccine and Reported Death
September 13, 2011
- MHLW Director-General Kikura Indicates “Firm Resolve” for Structural Improvement to Eliminate Drug Disasters
September 12, 2011
- Japan-China Pharma Regulators to Start 4 Projects to Boost Cooperation
September 12, 2011
- Regulatory Strategy Consultation Service “Not Off to a Good Start”: Mr Masuyama of PMDA
September 12, 2011
- Dispensing Fees per Prescription Down in FY2010 for 1st Time in 4 Years: Korosho
September 12, 2011
- MHLW Designates 6 Products Including ruxolitinib as Orphan Drugs
September 9, 2011
- Medical Costs Reduced ¥7 Bil. by Promoting Use of GEs: JHIA
September 9, 2011
- MHLW’s Council to Draw Up 10-Year Strategy for Hepatitis
September 9, 2011
- Council Recommends Subsidization of Peginterferon Therapy for Chronic Active Hepatitis B
September 9, 2011
- CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
September 8, 2011
- Generic Dispensing Not Promoted in Pharmacies: CSIMC’s Subcommittee
September 8, 2011
- CSIMC Introduces New Rule for Pricing of High-Priced Drugs; 10 Drugs to Be Reimbursed on Piecework under DPC
September 8, 2011
- Some CSIMC Members Question NHI Pricing of Nexium Priced at Lower Level Than Omepral
September 8, 2011
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…